Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

You may be eligible if

• Histologically confirmed metastatic adenocarcinoma of the colon or rectum
• * Not amenable to surgical resection
• * Recurrent or persistent disease after standard surgery, radiotherapy, and chemotherapy, including fluorouracil and irinotecan
• TAG-72 positive
• Performance status - ECOG 0-2
• WBC greater than 3,500/mm\^3
• Platelet count greater than 125,000/mm\^3
• Hemoglobin greater than 10 g/dL
• No nucleated RBC or significant teardrop RBC morphology
• Bilirubin less than 1.5 mg/dL
• SGOT/SGPT less than 4 times normal
• Hepatitis B surface antigen negative
• Creatinine less than 2.0 mg/dL
• HIV negative
• No other malignancy within the past 5 years except basal cell skin cancer
• No allergy to iodine
• No detectable antibody to monoclonal antibody CC49
• Not pregnant or nursing
• Fertile patients must use effective contraception
• At least 3 weeks since prior immunotherapy and recovered
• No prior bone marrow or stem cell transplantation
• No other concurrent immunotherapy
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy and recovered
• No concurrent chemotherapy
• See Disease Characteristics
• At least 3 weeks since prior radiotherapy and recovered
• No prior radiotherapy to more than 25% of red marrow
• No concurrent radiotherapy
• See Disease Characteristics
• At least 3 weeks since prior surgery and recovered